Nano-X Imaging Ltd. (NNOX) Q3 2022 Earnings Name Transcript

Nano-X Imaging Ltd. (NNOX 10.49%)
Q3 2022 Earnings Name
Nov 10, 2022, 8:30 a.m. ET

Contents:

• Ready Remarks
• Questions and Solutions
• Name Members

Ready Remarks:

Operator

Women and gents, thanks for standing by, and welcome to NANO-X third quarter 2022 earnings convention name. Right now, all members are in a listen-only mode. After the audio system’ presentation, there might be a question-and-answer session. [Operator instructions] Please be suggested that at present’s convention could also be recorded.

I’d now like to show the convention over to your speaker host, Mike Cavanaugh of investor relations. Please go forward.

Mike Cavanaugh — Investor Relations

Good morning, and thanks for becoming a member of us at present. Earlier at present, NANO-X IMAGING, LTD. launched its monetary outcomes for the quarter ended September 30, 2022. The discharge is presently out there on the Traders part of the corporate’s web site.

Erez Meltzer, chief govt officer; and Ran Daniel, chief monetary officer, will host this morning’s name. Earlier than we get began, I want to remind everybody that administration might be making statements throughout this name that embrace forward-looking statements concerning the corporate’s monetary outcomes, analysis and growth, manufacturing and commercialization actions, regulatory course of operations, and different issues. These statements are topic to dangers, uncertainties, and assumptions which are based mostly on administration’s present expectations as of at present and is probably not up to date sooner or later. Due to this fact, these statements shouldn’t be relied upon as representing the corporate’s views as of any subsequent date.

Elements which will trigger such a distinction embrace, however are usually not restricted to, these described within the firm’s filings with the Securities and Alternate Fee. We will even seek advice from sure non-GAAP monetary measures to offer extra data to traders. A reconciliation of the non-GAAP to GAAP measures is supplied with our press launch, with the first variations being amortization of intangible belongings, share-based compensation, secondary providing bills, goodwill impairment, change in obligation in connection of acquisitions and authorized charges in reference to class motion litigation, and the SEC inquiry. I might now like to show the decision over to Erez Meltzer.

Erez Meltzer — Chief Govt Officer

Thanks, Mike, and thanks all for becoming a member of the decision at present. Reporting on our third quarter of 2022, I am happy with the outcomes our group has been capable of ship as we proceed to advance our commercialization of the Nanox.ARC system. As in our final name, I’ll give an summary of our latest achievements and can share our outlook for the remainder of 2022 earlier than turning the decision over to Ran Daniel, our CFO, to evaluate our monetary ends in element. We’ll then open the decision as much as questions.

I am happy with the progress our group made throughout the quarter, which, as most of you realize, consists of our first 10-Okay submission to the FDA for our multisource Nanox.ARC system on the finish of September and which is now underneath FDA evaluate. I am very happy with the laborious work behind the scenes by our regulatory, product, and different groups to soak up the continual suggestions from our Q-submission course of and incorporate it into the analysis submission. We would not have any insights into the timing of the FDA’s response. In different regulatory information, we proceed to pursue CE Mark approval within the European Union, and I am glad to report that now we have engaged with BSI, the notified physique with whom we are going to work throughout this course of.

We sit up for offering updates to you as the method advances within the coming month. I might prefer to take a couple of minutes now to debate our progress towards commercialization of the multisource Nanox.ARC system. It stays our objective to start to deploy the multisource Nanox.ARC system in 2022, and we proceed to push towards the objective. We proceed to advance the method towards deployments of the multisource Nanox.ARC in Nigeria, topic to regulatory approval, as we not too long ago acquired an import license.

We intend to ship the primary system and start coaching quickly as we purpose to safe regulatory approval. Globally, now we have a complete of 6,850 preordered models. We imagine that after we start to deploy the multisource Nanox.ARC in Nigeria and in different early adopting nations, well being system hospitals and distributors will see the service that the Nanox.ARC offers. Scientific Updates.

We now have acquired the Helsinki allow to conduct medical trials in Israel utilizing our multisource Nanox.ARC system. We anticipate that the outcomes of those trials will generate medical pattern photographs of a number of physique organs throughout the fourth quarter of 2022. Now, turning to our AI and teleradiology enterprise segments. We proceed to see income from these necessary enterprise segments.

I am glad to report that throughout the third quarter of 2022, we signed 9 new consumer agreements for teleradiology providers, and we proceed to see income progress in these providers pushed by new consumer additions, in addition to natural progress from current shoppers. These companies generated top-line income of $2.4 million within the third quarter of 2022, in comparison with $2.2 million within the second quarter of 2022. Ran will evaluate the financials in additional element, however these revenues proceed to display the viability and utility of those extra providers to the healthcare programs, which providers are meant to be a part of a totally built-in multisource Nanox.ARC system upon deployment and an integral a part of our ecosystem and end-to-end answer. Earlier than I flip the decision over to Ran, I might prefer to remind everybody that we’ll be internet hosting a multisource Nanox.ARC demonstration broadcast with a stay viewers in Neve Ilan on Wednesday, November sixteenth, at 9:30 a.m.

Jap time. Because of the capability limitation, we invite you to attend just about. You could find the hyperlink for registration on our web site. I wish to thank our traders for his or her continued assist of our imaginative and prescient to assist make medical imaging accessible all through the world.

I am very proud of the progress we made this quarter, and we sit up for assembly extra milestones as we transfer towards large-scale commercialization. With that, I might like to show the decision over to Ran Daniel, chief monetary officer, to evaluate our monetary outcomes.

Ran Daniel — Chief Monetary Officer

Thanks, Erez. We reported a GAAP web loss for the third quarter of 2022 of $19.1 million, in contrast with a web lack of $13.5 million within the third quarter of 2021, which elevated largely because of the consolidations of Nanox.AI and USARAD with the corporate because the fourth quarter of 2021, a rise in our analysis and growth bills, and improve in our normal and administrative bills, which was mitigated by a lower in our gross sales and advertising and marketing bills and a 1.0 million expense as a result of a change in our obligation in connection of acquisition. Revenues for the third quarter of 2022 was $2.4 million, and gross loss was $1.4 million. Income from teleradiology providers for a similar interval was $0.3 million, with a gross revenue of $0.6 million on a GAAP foundation and a gross revenue of $1.2 million on a non-GAAP foundation, which represents a gross revenue margin of roughly 49.4%.

The rise within the firm’s income and the gross revenue margin within the third quarter of 2022 is because of revenues from an information monetization venture with a complete income of $0.3 million. Income from licensing of AI functions for a similar interval was $0.1 million, with a gross lack of $2.1 million on a GAAP foundation and 0.0 million on a non-GAAP foundation. Analysis and growth bills for the third quarter of 2022 have been $6.1 million as in comparison with $3.7 million for the comparable interval in 2021. The rise in our analysis and growth bills was primarily because of the consolidation of Nanox.AI with the corporate, in addition to because of the growth of the multisource Nanox.ARC and the Nanox.CLOUD and share-based compensation.

Gross sales and advertising and marketing bills for the third quarter of 2022 have been $0.7 million as in comparison with $1.5 million for the comparable interval in 2021. The lower was primarily as a result of a lower in price of labor and share-based compensation. Normal and administrative bills for the third quarter of 2022 have been $10.6 million as in comparison with $8.2 million for the comparable interval in 2021. The rise was due largely to the consolidation of Nanox.AI and USARAD with the corporate because the fourth quarter of 2021, a rise within the firm’s headcount and the general group infrastructure, and a rise within the firm’s authorized charges because of the U.S.

Securities and Alternate Fee inquiry and sophistication motion litigation, as described within the firm’s Type 6-Okay filed at present and Type 20-F from the 12 months ended December thirty first, 2021, filed on Might 2nd, 2022. Change in obligation in connection of acquisitions was $1.0 million as in comparison with none within the comparable interval because of the improve within the firm’s contingent earnout legal responsibility. The non-GAAP web loss for the third quarter of 2022 was $8.1 million, in comparison with a non-GAAP web lack of $8.4 million for a similar interval in 2021. A reconciliation between GAAP web loss and non-GAAP web loss for the third quarter of 2022 and 2021 is supplied within the monetary outcomes which are a part of the press launch we issued this morning.

Turning to our stability sheet. As of September thirtieth, 2022, we had money, money equivalents, and marketable securities of roughly $117.1 million, and we had $3.5 million in loans from financial institution. We ended the quarter with property and tools web of $44.1 million in contrast with $37.4 million as of December thirty first, 2021. The rise is basically because of the buying the lengthy lead gadgets for our multisource programs and equipment and tools for our fabrication facility in South Korea.

As of September thirtieth, 2022, we had roughly 52.3 million shares excellent versus 51.8 million shares excellent as of December thirty first, 2021. The rise was primarily because of the train of inventory choices. With that, I’ll hand the decision again over to Erez.

Erez Meltzer — Chief Govt Officer

 Thanks, Ran, for the monetary replace. And as soon as once more, thanks all for becoming a member of us at present. I really feel superb about NANO-X’s ends in the third quarter as CEO, however all of us acknowledge there’s extra to do. We hope to offer extra updates within the coming weeks and months.

With that, I might prefer to now open the decision for questions. Operator, please start the Q&A session.

Questions & Solutions:

Operator

Thanks. [Operator instructions] Please stand by whereas we compile the Q&A roster. And our first query coming from the road of Jeffrey Cohen with Ladenburg. Your line is open.

Jeffrey Cohen — Ladenburg Thalmann and Firm — Analyst

Howdy, Erez and Ran. How are you?

Erez Meltzer — Chief Govt Officer

Nice. And also you, Jeff?

Jeffrey Cohen — Ladenburg Thalmann and Firm — Analyst

Simply positive. So, a number of questions for you. I assume, firstly, so far as Nigeria and models which are perhaps out there for placement, may you give us a way of manufactured ARC models as they stand in the intervening time?

Erez Meltzer — Chief Govt Officer

By way of manufacturing, we’re, as we are saying, within the course of. We now have all of the supplies which is on the market. We’re making — really, we work hand at hand with the regulatory approvals. So, as soon as we get all of the paperwork, we will begin to ship the models.

And it goes the identical with the opposite nations after we get the — all of the regulation approvals. Simply to finish the reply about Nigeria, the following step is ship the primary unit for demonstration. The demo middle is prepared already over there. After which to interact with these clients who’re anticipating to get the machines, to do the coaching.

As you realize, we have indicated the work that we do with BVGH for the deployment and the coaching in Nigeria. So, that is the method that we do.

Jeffrey Cohen — Ladenburg Thalmann and Firm — Analyst

Are you able to give us a way of the scale of the order over the approaching 12 months particular to Nigeria?

Erez Meltzer — Chief Govt Officer

We do not — as you realize, and I will persist with it till additional or later or future different indications, we have not given a quantity thus far. The primary motive, in fact, was the relation. However we have not given a quantity thus far, and we might change it sooner or later.

Jeffrey Cohen — Ladenburg Thalmann and Firm — Analyst

Obtained it. OK. And leaping over to the teleradiology. May you give us a way of the variety of accounts and account progress and/or utilization traits and utilization progress?

Erez Meltzer — Chief Govt Officer

OK. Ran, would you want to deal with this query?

Ran Daniel — Chief Monetary Officer

Sure. Jeffrey, we had a further 9 accounts this quarter. The whole accounts is roughly 400 as of now. And so, you may calculate your self the expansion price for the 12 months.

Erez Meltzer — Chief Govt Officer

Mainly, you see the numbers when it comes to the revenues, the expansion charges. We’re nonetheless ready for all of the approvals and licenses that — and the accreditation that we’re ready all the time. After we signal, there’s a hole between the time that we will begin — do the readings. However proper now, the — when it comes to the shoppers, as all the time, now we have the type of, I’d say, 60-40 or 70-30, the place a number of clients are producing just about of the, I’d say, majority, a minimum of 60% of the revenues.

And proper now, what we see is a whole lot of progress in these which were with us for fairly a while. And we see the long run as nicely.

Jeffrey Cohen — Ladenburg Thalmann and Firm — Analyst

OK. Obtained it. After which may you discuss in regards to the couple of million of goodwill impairment for the quarter? Is there extra to impair? I can see the goodwill quantity, however will you anticipate any extra write downs of that goodwill quantity for the stability of the 12 months? Give us a way of what was written down for the third quarter.

Ran Daniel — Chief Monetary Officer

Sure. And simply to finish my reply earlier than to the brand new accounts, the [Inaudible] accounts. It takes us — as Erez mentioned, it takes us two to 3 months to undergo the credentialing course of as soon as we get the brand new consumer, simply to finish my different reply. As for the goodwill, the goodwill is actually — the goodwill impairment comes from a number of elements.

The 2 essential ones are, first, you realize, a change within the low cost price that we’re utilizing. And, you realize, so long as the Federal Reserve proceed to extend the charges, we must always count on to — a minimum of to be required to look at if we’re — impairment is required. And that is what we’re doing on a quarterly foundation. This particular quarter, there was no impairment, however there was indication that the impairment is required.

So, we needed to undergo the entire course of. As to your query for the third quarter impairment, there is no impairment expense, however now we have to undergo the entire course of. As for the fourth quarter, and you may also think about the truth that, you realize, we’ll have to contemplate all the time to make for the — for 2023 and going ahead, coupled with any change that might be within the low cost price that might be finished by the Federal Reserve.

Erez Meltzer — Chief Govt Officer

Now, you may think about, by the way in which, that after we begin on the level of the ARC, clearly, all of the teleradiology providers might be expanded and the expansion.

Jeffrey Cohen — Ladenburg Thalmann and Firm — Analyst

Obtained it. After which lastly, first, simply evaluate the place issues stand on the FDA so far as the permutations that we must always count on going ahead. We do anticipate that, clearly, a clearance can be one choice. The second can be that they’d be again with extra questions.

What are the few permutations that we may see?

Erez Meltzer — Chief Govt Officer

OK. The one factor that I do not guess or point out is the timing of the method from the FDA. And we noticed it within the final three years and I believe the entire world, the entire enterprise world. However we see it as we see it proper now.

What we’re saying that now we have finished the utmost or every thing that we may with a view to improve the probability of the clearance from the FDA. Having mentioned that, as I — I believe that — we spoke about it, and now we have emphasised that this 12 months, NANO-X has modified somewhat bit its regulatory technique from the single-step FDA submission course of to a stepwise method utilizing Q-submission take a look at for the questions and reply with the FDA group previous to the 510(okay) submission. And albeit talking, we intend to proceed to make use of this dialogue with the FDA as we develop the following era of the Nanox.ARC system, in addition to the long run merchandise that NANO-X will generate.

Jeffrey Cohen — Ladenburg Thalmann and Firm — Analyst

Excellent. OK. We sit up for subsequent week. Thanks for taking our questions right here, Erez. 

Erez Meltzer — Chief Govt Officer

Thanks.

Operator

Thanks. One second earlier than our subsequent query. Now, our subsequent query in queue coming from the road of Ross Osborn with Cantor. Your line is open.

Ross Osborn — Cantor Fitzgerald — Analyst

Hello. I hope everybody’s doing nicely. Congrats on the progress. 

Erez Meltzer — Chief Govt Officer

Hello. How are you? 

Ross Osborn — Cantor Fitzgerald — Analyst

Properly, thanks. So, is there any replace on the Ghana contract? I do know you famous a particular approval course of on final quarter’s name. So, in case you can present somewhat bit extra coloration simply on what the regulatory setting is there and sort of the place you stand in Ghana.

Erez Meltzer — Chief Govt Officer

You ask in regards to the Ghana deployment?

Ross Osborn — Cantor Fitzgerald — Analyst

Sure, that is appropriate.

Erez Meltzer — Chief Govt Officer

You recognize, we did it up till now, and we did it — we’ll do it sooner or later, that as quickly as now we have data which is required to be shared with the general public, we’ll do. We signed — as you realize, we signed the settlement. We’re ready for the regulatory processes. And as soon as we get the clearance, as we did now with Nigeria, or the approval, then we’ll launch it.

By the way in which, within the meantime, in fact, as we do with some other nations, then we do all of the preparations. So, we’re assembly with the shoppers, do preliminary trainings, checking all the provision of the Web and telecommunication infrastructure, attempting to see what is required when it comes to the coaching itself, and so forth., and so forth. And since now we have already mentioned that we count on that the preliminary deployment of the Nanox.ARC at scale, as we are saying, to be finished in — exterior of the U.S., then principally, that is the place we’re doing all of the stand-alone 3D digital tomosynthesis models. Our method is, proper now, to do the deployment within the U.S.

solely within the subsequent step, and we’ll inform after we really get the dialogue with the FDA as quickly as we will get it. We’re making all of the preparation, even within the nations that can require the FDA, particularly assembly distributors, attending to know higher the shoppers, the preparation of the regulatory processes, and so forth., and so forth. And so, as soon as we obtained the clearance, then we will really transfer quick ahead.

Ross Osborn — Cantor Fitzgerald — Analyst

Sounds nice. I assume only one extra on the Ghana contract. I do know you simply closed 350 models, however can you present us with a minimal annual price, if there’s a letter of credit score current within the contract?

Erez Meltzer — Chief Govt Officer

There’s all the time the distinction between ready and can. And the reply is that as quickly as now we have one thing to say, we are going to say.

Ross Osborn — Cantor Fitzgerald — Analyst

Honest sufficient. After which I assume trying forward of deployment, do you count on for the scan to be learn in Nigeria, or would these be outsourced to that? And if it’s the latter, you realize, do you could have radiologists in place? And are these radiologists, you realize, financially motivated to learn these scans?

Erez Meltzer — Chief Govt Officer

Proper now, proper now, based mostly on every thing that we all know proper now, which can change sooner or later, however based mostly on the research and the — on the groundwork that we did in Nigeria, it is going to be each.

Ross Osborn — Cantor Fitzgerald — Analyst

OK, nice. Thanks for taking my questions.

Erez Meltzer — Chief Govt Officer

Thanks, Ross.

Operator

One second, please, for our subsequent query. Now, our subsequent query in queue coming from the road of Suraj Kalia with Oppenheimer. Your line is open.

Suraj Kalia — Oppenheimer and Firm — Analyst

Good morning, Erez, Ran. How are you?

Erez Meltzer — Chief Govt Officer

Good. How are you, Suraj?

Suraj Kalia — Oppenheimer and Firm — Analyst

I am doing nicely. Hey, so there’s a bunch of questions. Erez, are you able to give us a — as you search for commercialization, for instance, to select it off in Nigeria, how would the workflow for these merchandise look, i.e., what occurs in Israel? What occurs in Korea, particularly your manufacturing facility? What occurs in Japan, ceramic or glass? Simply sort of stroll us by how the workflow is anticipated to occur.

Erez Meltzer — Chief Govt Officer

You recognize, it is attention-grabbing, and it is humorous. However really, what you’re asking for is a promo for subsequent week on the ARC Day. On the ARC Day, you will notice the entire circulate. As now we have defined prior to now, the chips are being manufactured in Korea.

The tubes are being put in in Korea. And we’re planning on doing extra of it sooner or later in different — from different suppliers. All the mixing and the meeting is being finished presently in Israel and can — sooner or later, as we mentioned within the prospectus and the 20-F, might be finished, — a part of it is going to be finished exterior of Israel. So, the system is totally put in and assembled in Israel, and when it ships, it ships really a number of in a field and shipped to the place that they’re going to be deployed.

In Nigeria, you requested particularly about Nigeria, however it is going to be the identical in different nations. We’re doing the set up, the connection to the community, to the system, generally, even to tax system sooner or later. We do all of the coaching of the operators. We do all of the coaching of the upkeep on web site.

We do the coaching of the radiologist on premise. We now have a demo middle. We may have a demo middle in each nation that we will deploy. And proper now, in Nigeria, now we have already the demo middle able to be — to put in the primary unit.

And what else? After which, in fact, the upkeep afterwards and the preliminary working of the models might be on the bottom. We work with companions in Nigeria. We’ll discover the work that we’re planning on doing with different companions as nicely. So, it is not just one, however it is going to be a number of of them.

We now have already engaged ourselves in a dialogue with the shoppers and hospitals in Nigeria, by the way in which, in different nations as nicely. So, that is really — I hope that I addressed intimately the reply to your query.

Suraj Kalia — Oppenheimer and Firm — Analyst

Honest sufficient. And there’s — I presume the Nigeria configuration is similar because the U.S. configuration.

Erez Meltzer — Chief Govt Officer

It is a good query. Hopefully, sure. However we do not know what might be — we hope that the FDA might be — will approve the identical as that now we have meant to make use of. And I hope that no adjustments will happen.

And the reply — so, principally, that is the reply.

Suraj Kalia — Oppenheimer and Firm — Analyst

Obtained it. And, Erez, lastly, the 6,800 or so confirmed preorders that you just talked about, how assured are you with the — with these contracts of their means to meet, you realize, your means to implement? As a result of a whole lot of them, you realize, our recollection is, you realize, they’re a minimum of a number of years outdated and haven’t gone by validation testing. So, any extra coloration can be significantly appreciated. Gents, thanks for taking my questions.

Erez Meltzer — Chief Govt Officer

OK. So, I am greater than — I believe they’re — I am greater than 40 years in enterprise, four-zero, and greater than 35 years as CEO. And the one factor I’ve discovered in enterprise, that principally, you’re assured within the deal and the transaction as soon as the cash is in your financial institution. Then this particular place when the cash from every certainly one of them might be in my — in our checking account.

So, that is with — when it comes to confidence. However having mentioned that, all of it depends upon the clearance processes and approvals and laws in any one of many place. We’re in steady dialogue with the — with these enterprise entities that we signed the settlement with. A couple of of them, by the way in which, are coming infrequently to Israel to see the progress and to see — to do some coaching and to get to know higher the system and the product and the meant use.

So, that is principally the reply.

Suraj Kalia — Oppenheimer and Firm — Analyst

Thanks.

Operator

Thanks. And one second, please, for our subsequent query in queue. And our subsequent query in queue coming from the road of Rahul Rakhit with LifeSci Capital. Your line is open.

Rahul Rakhit — LifeSci Capital — Analyst

Hey, guys. Thanks for taking the questions. I used to be simply questioning in case you may contact somewhat bit on the preliminary utilization ranges at Northwell and Spectrum Well being. Perhaps assist us higher perceive how to consider the income era from these IDNs transferring ahead.

Erez Meltzer — Chief Govt Officer

To start with, the — now we have not indicated particularly from every one of many IDNs, however I’ll add or I’ll say a few issues. The dialogue with one of many IDNs that now we have already offered and acquired the cash final 12 months, the settlement — or the extension of the settlement for subsequent 12 months is with a lot greater revenues coming from the IDN. By way of the Northwell this can be a steady dialogue. We now have the — over the, I believe, few hospitals that have been already put in as a part of the venture.

Northwell, I’d say, is extra than simply an IDN. They’re sort of strategic IDN that we work with, that we collectively develop some functions, we collectively develop some enterprise fashions and meant use of the AI software. They’re planning to undertake and set up all of the functions that now we have. We’re — as you realize, now we have two in place, and some others are coming quickly.

And final however not least, we’re within the last technique of growing the enterprise — the long run enterprise mannequin that can assist us to point what’s the worth that we deliver to the IDN, to the insurance coverage firm, to the pharmaceutical firm and to tailored to every certainly one of them, like what can be one of the best mannequin to ensure that our advantages to develop the enterprise, but in addition that they may get pleasure from from the added worth of our providers.

Rahul Rakhit — LifeSci Capital — Analyst

Obtained it. OK. Thanks. Thanks, guys.

Erez Meltzer — Chief Govt Officer

And, Rahul, only one extra sentence. We now have not indicated the quantity of income that we generated or going to generate from these two initiatives. However, now we have to keep in mind these are the 2 initiatives that now we have within the course of operations space.

Rahul Rakhit — LifeSci Capital — Analyst

Obtained it. No, I recognize that. Thanks. I simply need — are you able to discuss somewhat bit extra in regards to the medical trials that you just intend to conduct in Israel? And in case you can present any coloration on trial design or what photographs particularly you guys are specializing in initially and what you — and the way you propose to leverage that knowledge transferring ahead.

Thanks for taking the questions.

Erez Meltzer — Chief Govt Officer

We’ll replace as quickly as we full the — to getting the samples. And the one factor that we — now we have indicated that now we have acquired the Helsinki allow to conduct the medical trials at — in one of many main hospitals. The system is already put in there. The X-ray room is already put in there.

And we anticipate that the outcomes of those trials will — for us, will generate pattern of photographs of a number of physique organs throughout this quarter, the fourth quarter of 2022. I do hope, imagine, and anticipate that within the subsequent earnings name, we’ll be — we’ll have extra to share about it.

Operator

Thanks. And I’m displaying no additional questions presently. I’d now like to show the decision again over to Mr. Meltzer for any closing remarks.

Erez Meltzer — Chief Govt Officer

So, thanks all for taking the time to be with us. For these of you who’ve really extra curiosity in what now we have to point out and point out, we — I hope that subsequent week might be good for these — for these people who want to see. I thanks, all of the traders, for being with us. And we hope to meet our guarantees, the guarantees that we made to make every thing occur and to actually change the world in what we’re doing.

Operator

[Operator signoff]

Length: 0 minutes

Name members:

Mike Cavanaugh — Investor Relations

Erez Meltzer — Chief Govt Officer

Ran Daniel — Chief Monetary Officer

Jeffrey Cohen — Ladenburg Thalmann and Firm — Analyst

Ross Osborn — Cantor Fitzgerald — Analyst

Suraj Kalia — Oppenheimer and Firm — Analyst

Rahul Rakhit — LifeSci Capital — Analyst

Extra NNOX evaluation

All earnings name transcripts